Arbutus Biopharma (ABUS) Operating Expenses (2013 - 2026)

Arbutus Biopharma has disclosed Operating Expenses across 14 years of filings, most recently posting $10.2 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $10.2 million, down 62.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $35.0 million (down 60.7% YoY), and the FY2025 annual result was $52.2 million, down 36.67% from the prior year.
• Operating Expenses came in at $10.2 million for Q1 2026 at Arbutus Biopharma, up from $6.3 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $28.8 million in Q4 2022 to a low of $6.3 million in Q4 2025.
• The 5-year median for Operating Expenses is $23.0 million (2023), against an average of $20.3 million.
• Across the five-year window, Operating Expenses surged 35.19% in 2022 and sank 62.79% in 2026, its largest moves.
• Arbutus Biopharma's Operating Expenses stood at $28.8 million in 2022, then fell by 20.53% to $22.9 million in 2023, then slumped by 32.26% to $15.5 million in 2024, then plunged by 59.11% to $6.3 million in 2025, then surged by 61.14% to $10.2 million in 2026.
• The last three Operating Expenses figures came in at $10.2 million (Q1 2026), $6.3 million (Q4 2025), and $9.2 million (Q3 2025), per Business Quant data.